CD26
Synonyms
DPPIV, Dipeptidyl peptidase IV membrane form, T-cell activation antigen CD26, Adenosine deaminase complexing protein 2, Dipeptidyl peptidase IV soluble form, ADCP2, Dipeptidyl peptidase 4, ADCP-2, DPP4, Dipeptidylpeptidase IV (CD26, Adenosine Deaminase Complexing Protein 2), DPP IV, TP103, CD26, Dipeptidyl-Peptidase 4, CD26 Antigen, ADABP, Dipeptidylpeptidase 4, Dipeptidyl peptidase IV, Gly-Pro Naphthylamidase, Xaa-Pro-Dipeptidylaminopeptidase, Post-Proline Dipeptidyl Aminopeptidase IV,Description
Dipeptidyl peptidase IV (DPP4), also known as adenosine deaminase complexing protein 2 or CD26 (cluster of differentiation 26) is a protein that, in humans, is encoded by the DPP4 gene.Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline.
KO Status
F2 (-/-)
Drug Information
Launched drugs: 22
Drugs in clinical trials: 28
Latest Research Phase:Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Alogliptin Benzoate/Metformin Hydrochloride
Approved
Takeda Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT02763007
NCT02683226
NCT01890122
Intervention Type
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Polycystic Ovary Syndrome; Insulin Resistance
Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 3
Recruitment Status
Terminated
Completed
Completed
Evogliptin Tartrate/Metformin Hydrochloride
DA-1229_01
Approved
Dong-A Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT02375139
NCT03939143
NCT04326166
Intervention Type
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Type2 Diabetes
Diabetes Mellitus, Type 2
Study Phase
Phase 1
Phase 1
N/A
Recruitment Status
Completed
Completed
Recruiting
Vildagliptin
LAF-237, DSP-7238, LAF-237A, NVP-LAF-237
Approved
Novartis Pharma Ag
Prediabetic State, Diabetes Mellitus, Type 2, Renal Insufficiency, Kidney Diseases, Diabetes Mellitus
NCT Number
NCT01398592
NCT01582243
NCT03819127
NCT01757587
NCT01219400
NCT00975065
NCT02089438
NCT01541956
NCT02639130
NCT01882907
NCT01147276
NCT01193296
NCT01766778
NCT02142309
NCT03178591
NCT01679899
NCT02176681
NCT01238978
NCT01196546
NCT01426737
NCT01604213
NCT02145611
NCT01518101
NCT01686932
NCT01099137
NCT01472432
NCT01812122
NCT01309698
NCT01404676
NCT01867502
NCT01356381
NCT02528019
NCT01426802
NCT02475070
NCT01339143
NCT03014479
NCT04485845
NCT01862263
NCT02007278
NCT02312427
NCT03983551
NCT01910441
NCT02853630
NCT03693560
NCT01827280
NCT03958591
NCT01758380
NCT02002221
NCT01649466
NCT01565096
NCT00894868
NCT01528254
NCT03804411
NCT03253562
NCT04654676
NCT00351832
NCT00260156
NCT00101803
NCT00952991
NCT03088670
NCT01559025
NCT00325117
NCT01497522
NCT01822548
NCT00368134
NCT00099931
NCT00101712
NCT00099892
NCT01262586
NCT00380445
NCT01242228
NCT00102388
NCT01000688
NCT00237250
NCT03925701
NCT00351884
NCT00383578
NCT00765830
NCT01159249
NCT00728351
NCT01233622
NCT00138606
NCT00351585
NCT00101673
NCT01122641
NCT00468039
NCT00325429
NCT00106340
NCT01224366
NCT00351507
NCT00102466
NCT00099853
NCT00396071
NCT01257451
NCT00382096
NCT00494884
NCT00389415
NCT00351546
NCT01871558
NCT00138567
NCT00646542
NCT00120536
NCT00138619
NCT00312130
NCT00616811
NCT00396357
NCT00300287
NCT00651105
NCT00237237
NCT00770081
NCT01582230
NCT00390520
NCT00380380
NCT00099944
NCT00099918
NCT02849899
NCT00138593
NCT00110240
NCT00396227
NCT00099905
NCT00099866
NCT00822211
NCT00138515
NCT00138554
NCT00138541
NCT00138580
NCT01357252
NCT00230464
NCT00821977
NCT00860288
NCT00936234
NCT01018602
NCT00238498
NCT01346254
NCT02803892
NCT00099957
NCT00980356
NCT01452113
NCT00818571
NCT04410341
NCT00633997
NCT00567047
NCT02816970
NCT00414947
NCT01537120
NCT02749032
NCT00572650
NCT01582308
NCT00419887
NCT03939624
NCT03577184
NCT02506296
NCT02476760
NCT01588587
NCT01162772
NCT01083992
NCT03492580
NCT02456428
NCT04017221
NCT01176708
NCT03918148
NCT02475499
NCT01963130
NCT02862470
NCT02244164
NCT01703637
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug;Device
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus Type 2
Diabetes Mellitus, Type 2
Mild Cognitive Impairment
Type 2 Diabetes
Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Diabetes; Hypoglycemia
Type 2 Diabetes Mellitus
Type-2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Type 2; Ischemic Heart Disease
Type 2 Diabetes Mellitus; Menopause; Osteoporosis; Osteopenia
Haemodialyzed, Type 2 Diabetes
Type 2 Diabetes Mellitus; Elderly
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus; Ischemic Heart Disease
Type 2 Diabetes Mellitus; Hypertension; Endothelial Dysfunction
Type 2 Diabetes
Diabetes Mellitus Type 2
Diabetes
Chronic Foot Ulcers
Diabetes Mellitus, Non-Insulin-Dependent
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; Hypoglycemic Agents; Diabetic Blood Glucose Monitoring; Exercise
Type 2 Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus; Oxidative Stress
Type 2 Diabetes
Metabolic Syndrome; Diabete Type 2; Kidney Insufficiency
Type 2 Diabetes Mellitus
Type 2 Diabetes; Hypoglycemia
Heart Failure; Diabetes Mellitus
Type 2 Diabetes Mellitus; Proteinuria
Type 2 Diabetes Mellitus
TYpe 2 Diabetes Mellitus
Coronary Artery Disease; Diabetes Mellitus, Type 2
1- Microvascular Function; 2-oxidative Stress; 3-inflammation
Poorly Controlled Diabetes Mellitus; Intensive-de-escalation Therapy; Long-term Regimen Simplification
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Diabetes Mellitus Type II
Congestive Heart Failure; Type II Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Type 2
Type 1 Diabetes; Insulin Dependent Diabetes; Juvenile Onset Diabetes Mellitus; Autoimmune Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type II Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes; Endothelial Dysfunction
Prediabetic State
dm
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Renal Insufficiency
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Insulin Resistance; Microvascular Disease
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Pre-diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type-2 Diabetes; Healthy
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Renal Insufficiency
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Disorder Related to Renal Transplantation; Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Insulin-dependent Gestational Diabetes
Diabetes Mellitus, Type 2
Impaired Glucose Tolerance; Kidney Transplantation
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes Mellitus
Diabetes Mellitus
Renal Impairment; Diabetes
Major Depressive Disorder
Diabetes Mellitus, Type 2
Type-2 Diabetes
Healthy
Healthy
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Healthy
Type2 Diabetes; Myocardial Infarction; Ischemic Stroke; Cardiovascular Death; Heart Failure; All-Cause Mortality
Diabetes Mellitus, Type 2
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus; Cardiovascular Risk; Endothelial Dysfunction
Non-Alcoholic Fatty Liver Disease
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation
Liver Transplantation
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Drug Mechanism; Drug Usage
Thyroid Cancer
Type 2 Diabetes; Incretinomimetics; Pancreas
Type 2 Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Completed
Completed
Unknown status
Completed
Recruiting
Terminated
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Not yet recruiting
Completed
Completed
Completed
Unknown status
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Withdrawn
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Unknown status
Unknown status
Unknown status
Completed
Completed
Completed
Unknown status
Recruiting
Completed
Completed
Active, not recruiting
Recruiting
Unknown status
Gosogliptin
PF-734200, PF-00734200
NDA/BLA
Pfizer Pharmaceuticals Ltd (China)
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
NCT Number
NCT03088670
NCT00473525
NCT00618007
NCT00596518
Intervention Type
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Renal Insufficiency, Chronic
Study Phase
Phase 3
Phase 2
Phase 2
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Cetagliptin/Metformin
Preclinical
Shengshi Taike Biological Medicine Technology (Suzhou) Co Ltd
Diabetes Mellitus, Type 2
Anagliptin
SK-0403, CWP-0403
Approved
Sanwa Kagaku Kenkyusho Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT02528019
NCT02312427
NCT03014479
NCT02330406
NCT01529541
NCT01529528
NCT00532506
NCT01169090
NCT00888719
NCT01131091
NCT04267601
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Heart Failure; Diabetes Mellitus
Type 2 Diabetes
Dipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus; Coronary Disease
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 1
N/A
Recruitment Status
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Empagliflozin/Linagliptin/Metformin
Approved
Boehringer Ingelheim Gmbh, Eli Lilly And Company
Diabetes Mellitus, Type 2
NCT Number
NCT03259490
NCT02821910
Intervention Type
Drug
Drug
Indications
Healthy
Healthy
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride
Approved
Astrazeneca Plc
Diabetes Mellitus, Type 2
Linagliptin/Metformin Hydrochloride
Approved
Boehringer Ingelheim Gmbh
Diabetes Mellitus, Type 2
NCT Number
NCT01708902
NCT02221414
NCT01383356
NCT02220647
NCT01216397
NCT02084082
NCT02121509
NCT01903356
NCT03807440
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Healthy
Healthy
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Study Phase
Phase 3
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride
Approved
Lg Life Sciences Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT04070794
NCT02670018
NCT01747083
Intervention Type
Drug
Drug
Drug
Indications
Type2 Diabetes
Healthy
Type 2 Diabetes
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Not yet recruiting
Unknown status
Completed
Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride
Approved
Handok Inc
Diabetes Mellitus, Type 2
NCT Number
NCT03787043
NCT03787017
NCT02305095
Intervention Type
Drug
Drug
Drug
Indications
Healthy Volunteers
Healthy Volunteers
Heart Failure
Study Phase
Phase 1
Phase 1
N/A
Recruitment Status
Completed
Completed
Active, not recruiting
Sitagliptin Phosphate Monohydrate
MK-431, MK-0431, ONO-5435, ONO-5435A, L-000224715
Approved
Merck Sharp & Dohme Corp
Diabetes Mellitus, Type 2, Renal Insufficiency, Glucose Intolerance, Dyslipidemias, Hepatic Insufficiency, Diabetes Mellitus, Kidney Failure, Chronic
NCT Number
NCT00780715
NCT00969566
NCT01131182
NCT02653209
NCT00729326
NCT01718093
NCT00964184
NCT01859793
NCT03804411
NCT02333591
NCT01337440
NCT02122380
NCT02294084
NCT02920918
NCT02802644
NCT02188186
NCT01717911
NCT00833027
NCT01112670
NCT02250794
NCT00732121
NCT03267576
NCT03893526
NCT01660386
NCT01195090
NCT00740363
NCT01449747
NCT00766441
NCT00939939
NCT00364377
NCT02301806
NCT01100125
NCT03108521
NCT02528019
NCT00968006
NCT04287387
NCT02060383
NCT01845831
NCT01235819
NCT02015910
NCT00627744
NCT02941445
NCT03959501
NCT02330406
NCT02743260
NCT02263677
NCT01907854
NCT01686932
NCT01610154
NCT02639637
NCT01519674
NCT02312063
NCT02312427
NCT02192853
NCT01709305
NCT00666848
NCT02653131
NCT01471808
NCT00832624
NCT01099618
NCT02480465
NCT01490918
NCT01186562
NCT02406443
NCT02556918
NCT01096277
NCT03813316
NCT01744236
NCT01341717
NCT01193296
NCT00978796
NCT02041234
NCT04495881
NCT02318693
NCT02655757
NCT00847080
NCT02917031
NCT02527993
NCT04323189
NCT00936663
NCT01374568
NCT01530178
NCT00870194
NCT00885638
NCT02386943
NCT00820573
NCT01701973
NCT03014479
NCT01378117
NCT02256189
NCT03738878
NCT00832390
NCT04298684
NCT02365233
NCT02836704
NCT00686634
NCT03717688
NCT01847144
NCT02607410
NCT03122041
NCT01970462
NCT00957060
NCT01895569
NCT02741687
NCT02338921
NCT02089438
NCT02315287
NCT01863147
NCT03602638
NCT00699322
NCT02373865
NCT00477581
NCT02443402
NCT02048904
NCT01928199
NCT02072096
NCT01890629
NCT00541775
NCT02577003
NCT00086502
NCT00372060
NCT00397631
NCT00976937
NCT00875394
NCT01590797
NCT01702298
NCT03125694
NCT00722371
NCT00509236
NCT01552694
NCT02791490
NCT01106625
NCT04017832
NCT01937598
NCT00350779
NCT00289848
NCT01340768
NCT02946632
NCT01477853
NCT01242228
NCT01098539
NCT01841697
NCT01829464
NCT00094757
NCT02623998
NCT03115112
NCT00701090
NCT00363844
NCT00363519
NCT01076075
NCT01794143
NCT00305604
NCT01984606
NCT01462266
NCT02226003
NCT00094770
NCT00425490
NCT00541450
NCT02567994
NCT02036515
NCT02406950
NCT01834274
NCT01602003
NCT02577016
NCT01038648
NCT00837577
NCT01289990
NCT01472367
NCT01999218
NCT01189890
NCT00106704
NCT01106690
NCT02452632
NCT02738879
NCT01545388
NCT00790205
NCT00363948
NCT00087516
NCT00449930
NCT00482729
NCT02284893
NCT00885352
NCT04365517
NCT00660075
NCT00851903
NCT03061214
NCT01590771
NCT00411411
NCT01703221
NCT01549964
NCT01517321
NCT00086515
NCT00532935
NCT00545584
NCT00984867
NCT01106677
NCT02099110
NCT00337610
NCT00676338
NCT01529541
NCT02532855
NCT00853944
NCT00700817
NCT00616811
NCT00854035
NCT01046110
NCT01485614
NCT00813995
NCT00967798
NCT02675335
NCT00789191
NCT01678820
NCT00509262
NCT00103857
NCT00395343
NCT02536248
NCT00095056
NCT01930188
NCT01177384
NCT01028391
NCT01296412
NCT01334229
NCT01081834
NCT00855166
NCT01034111
NCT02377388
NCT00411554
NCT02564211
NCT01076088
NCT00734474
NCT00650143
NCT04271189
NCT00821977
NCT04409795
NCT01600703
NCT00683735
NCT02882477
NCT01093651
NCT02111096
NCT02127047
NCT00881530
NCT01936025
NCT00481663
NCT01336322
NCT01824264
NCT00371007
NCT01376323
NCT01155284
NCT00862719
NCT02324010
NCT01991197
NCT02647320
NCT01720264
NCT03359590
NCT01257464
NCT02683525
NCT01059825
NCT01963845
NCT02689362
NCT00482079
NCT02513771
NCT00716092
NCT00768651
NCT00631488
NCT00947011
NCT00451113
NCT04448587
NCT00961363
NCT02347501
NCT00127192
NCT01405911
NCT01119846
NCT01035879
NCT00901979
NCT00837759
NCT00420511
NCT01969357
NCT01128621
NCT01414920
NCT02576288
NCT00758069
NCT04268563
NCT01159847
NCT00733577
NCT00961857
NCT00783549
NCT00551590
NCT01408888
NCT00696826
NCT00541229
NCT00830076
NCT01104532
NCT01095991
NCT02956044
NCT00929201
NCT03790839
NCT02824874
NCT00975052
NCT02650427
NCT00842556
NCT02172196
NCT02363335
NCT00511108
NCT01093794
NCT00944450
NCT03646721
NCT00888238
NCT01567540
NCT00971659
NCT01422590
NCT00960453
NCT02749032
NCT00813228
NCT00704132
NCT01820104
NCT01582308
NCT01557504
NCT02683187
NCT01441232
NCT02328040
NCT01721382
NCT03115099
NCT00418366
NCT01054118
NCT00642798
NCT00501657
NCT02827890
NCT00842400
NCT00730275
NCT00657280
NCT02444364
NCT02493959
NCT01354990
NCT01879228
NCT04192292
NCT01642108
NCT03180281
NCT00696982
NCT00426413
NCT01073826
NCT01357135
NCT00466518
NCT00790348
NCT01227460
NCT01545024
NCT03659461
NCT02940184
NCT02879409
NCT01703637
NCT01342939
NCT04295005
NCT00673894
NCT01065766
NCT03939624
NCT01413542
NCT04149067
NCT04061473
NCT01855087
NCT01357148
NCT00659711
NCT03233178
NCT02628392
NCT01198730
NCT01767389
NCT01741103
NCT01140438
NCT01316835
NCT01162772
NCT01077323
NCT03918148
NCT00721552
NCT00747383
NCT00806520
NCT02336659
NCT01092663
NCT01183104
NCT01062048
NCT01341795
NCT02900417
NCT02130687
NCT02244164
NCT01588587
NCT01272583
NCT00881543
NCT00795275
NCT01512797
NCT01260246
NCT01006018
NCT01901861
NCT02443922
NCT02456428
NCT02475499
NCT01951339
NCT04017221
NCT01944618
NCT03936062
NCT02077946
NCT01488279
NCT03492580
NCT01751321
NCT00775684
NCT02140645
NCT02138097
NCT03078049
NCT01332370
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug;Dietary Supplement;Device
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Device
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Behavioral
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Other;Dietary Supplement
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Other
Drug
Other
Drug
Drug
Other;Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Biological;Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Diabetes
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 1 Diabetes
Diabetes Mellitus, Type 2
Diabetes; Atherosclerosis
Diabetes Mellitus, Type 2
Coronary Microvascular Dysfunction
Type 2 Diabetes Mellitus; Chronic Liver Disease
Polycystic Ovary Syndrome
Neoplasms, Adipose Tissue
Heart Failure, Systolic; Diabetes Mellitus, Type 2
Acute Coronary Syndrome; Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes
Diabetes Mellitus
Healthy
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Glucose Intolerance
Type 2 Diabetes Mellitus
Diabetes; Hypoglycemia
Diabetes Mellitus Type 2
Pre-diabetes
Type 2 Diabetes
Diabetes
Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type 2 Diabetes Mellitus
Type2 Diabetes Mellitus
Cushing's Disease; Acromegaly
Type 2 Diabetes
Type 1 Diabetes
Type II Diabetes
Myocardial Infarction; Unstable Angina Pectoris; Diabetes Mellitus; Impaired Glucose Tolerance
Polycystic Ovary Syndrome; Body Weight
Type 2 Diabetes; Ketonemia
Dipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus; Coronary Disease
Healthy
Type 2 Diabetes; Non-alcoholic Fatty Liver Disease
Diabetes; Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2
Insulin Secretion; Insulin Resistance
Type 2 Diabetes Mellitus
Diabetes; Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Heart Failure; Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Metabolic Syndrome; Hypertension
Short Bowel Syndrome
Diabetes Mellitus, Type 2
Diabetes Mellitus Non-insulin-dependent
Ketosis Prone Diabetes; Diabetes Ketoacidosis; Hyperglycemia
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Pancreatitis; Diabetes
Type 2 Diabetes
Hyperglycemia
Type 2 Diabetes Mellitus
Type2 Diabetes
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 1 Diabetes
Type II Diabetes in Subjects BMI 27 to 32
Type 2 Diabetes
Type 2 Diabetes Mellitus
Atherosclerosis; Type 2 Diabetes Mellitus
Reactive Hypoglycemia
Type 2 Diabetes Mellitus; Heart Failure
Hypoglycemia; Obesity; Surgery
Genetics Disease; Type2 Diabetes; Heart Failure
Type 2 Diabetes; End Stage Renal Disease
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 1
Type 2 Diabetes Mellitus
Healthy; Type 2 Diabetes
Type 2 Diabetes
Diabetes
Obesity
Type 2 Diabetes
Type 2 Diabetes Mellitus; Hospitalization; Hyperglycemia
Type 2 Diabetes
Hypertension
Diabetes Mellitus
Diabetes Mellitus, Type 2; Thyroid Nodule (Benign)
Type II Diabetes; Nonalcoholic Fatty Liver
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes; Heart Failure
Type 2 Diabetes
Type 2 Diabetes Mellitus
PCOS
Diabetes Mellitus, Type 2; Hyperglycemia
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Hyperglycemia
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Newly Diagnosed Type 2 Diabetes; Coronary Artery Disease
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Type 2 Diabetes
Diabetes Mellitus Type 2
Type 2 Diabetes Mellitus
Coronary Artery Disease
Type 2 Diabetes; Microalbuminuria
Posttransplant Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Uncontrolled Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; End-Stage Kidney Disease
Inflammation; Macrophage Infiltration; Cardiovascular Disease
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes
Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus, Non Insulin Dependent; Diabetes Mellitus, Non-Insulin-Dependent
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Healthy
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Covid19; Diabetes Mellitus, Type 2; CKD
Diabetes Mellitus; Postprandial Lipemia
Diabetes Mellitus, Type 2
Diabetes; Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Glycemic Control
Type 2 Diabetes
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Islet Transplantation
Diabetes; Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes; Diabetes Mellitus, Type 2
Diabetes Mellitus; Type 2 Diabetes
Type 2 Diabetes Mellitus
Cystic Fibrosis; Prediabetes
Diabetic Foot
Diabetes; Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; Chronic Renal Insufficiency
Diabetes; Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes
Platelet Aggregation During Acute Myocardial Infarction
Diabetes Mellitus, Non-Insulin-Dependent
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Acute Myocardial Infarction
Newly Diagnosed Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 1 Diabetes; Monogenic Diabetes
Hyperlipidemia
Diabetes
Diabetes Mellitus; Iron Metabolism Disorders; Gastroduodenal Ulcer; Optic Atrophy; Sensorineural Hearing Loss; Platelet Dysfunction
Diabetes; Insulin Resistance
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 1
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type II Diabetes Mellitus
Pre-diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 1 Diabetes
Leukemia, Myeloid, Acute; Acute Lymphoblastic Leukemia; Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin
Gastroparesis; Diabetes Mellitus
Psoriasis; Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Hematopoetic Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin
Pharmacological Action
Cystic Fibrosis
Graft vs Host Disease; Hematopoietic Stem Cell Transplantation
Diabetes Mellitus, Type 2
Non-alcoholic Fatty Liver Disease
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type II
HIV-1 Infection
Diabetes Mellitus, Type 2
Type 1 Diabetes
Diabetes Mellitus, Type 2
Glucose Homeostasis
Type 2 Diabetes
Graft Vs Host Disease
Impaired Glucose Tolerance
Psoriasis
Type 2 Diabetes Mellitus
Glucose Intolerance
Diabetes Mellitus, Type 2
Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 1; Autoimmune Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Atherosclerosis; Inflammation
Diabetes Mellitus, Non-Insulin-Dependent
Polycystic Ovary Syndrome; Infertility; ART
Type 1 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes
Dyslipidaemias
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Liver Insufficiency
Type 2 Diabetes
Type 2 Diabetes Mellitus
Healthy; Pharmacokinetics of ASP1941
Type 2 Diabetes Mellitus
Type2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Patients
Diabetes Mellitus, Type II
Type 2 Diabetes
Hepato Carcinoma
Type 2 Diabetes Mellitus
Healthy
Healthy Volunteers
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Hepatitis C
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus Type 1; Diabetes Mellitus Type 2
Type 2 Diabetes Mellitus (T2DM)
Healthy
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Healthy
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 1
Cystic Fibrosis
Diabetes Mellitus, Type 2
Renal Insufficiency; Hemodialysis
Diabetes Mellitus, Type 2
Diabetes Mellitus Non-insulin-dependent
Gastroparesis; Diabetes Mellitus
Diabetes Mellitus Type 2
Obesity
Type 2 Diabetes
Heart Failure, Congestive
Type 2 Diabetes
Healthy
Diabetes Mellitus, Type 2
Cystic Fibrosis; Pancreatic Insufficiency
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus; Arterial Stiffness
Ketosis Prone Diabetes; Diabetic Ketoacidosis; Severe Hyperglycemia
Diabetes Mellitus, Type 2; Obesity
Type 2 Diabetes Mellitus
Kidney Transplant; Type 2 Diabetes
Type 2 Diabetes
Type 1 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus; PreDiabetes
Physiology
Diabetes Mellitus Type 2
Type 2 Diabetes Mellitus
Maturity-onset Diabetes of the Young
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type2 Diabetes; Myocardial Infarction; Ischemic Stroke; Cardiovascular Death; Heart Failure; All-Cause Mortality
Hypertension; Diabetes Type 2
Diabetes Mellitus, Type 2
Diabetes After Total Pancreatectomy
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes
T2DM (Type 2 Diabetes Mellitus); Fatty Liver; NAFLD
Type2 Diabetes Mellitus
Diabetes Mellitus; Coronary Artery Disease
Diabetes Mellitus, Type 2
Diabetes Type I
Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus; Cardiovascular Risk; Endothelial Dysfunction
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies); Healthy Subjects (Treated With no Diabetes Therapies)
Type 2 Diabetes Mellitus
Diabetes Mellitus; Steroid Diabetes; Glucocorticoid-induced Diabetes; Beta-cell Function
Type 2 Diabetes Mellitus
Type 2 Diabetes
Severe Obesity
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus; Hypertension
Type 2 Diabetes; Incretinomimetics; Pancreas
Type 2 Diabetes Mellitus
Type 1 Diabetes; Hypoglycemia
Diabetes Type 2
Obesity
Type 2 Diabetes Mellitus
Type 2 Diabetes; Nonalcoholic Steatohepatitis
Prediabetic State
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes; Cardiovascular Disease
Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation
Type 2 Diabetes
Diabetes
Diabetes; Diabetes Mellitus, Type 2
Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Type 2 Diabetes
Pre-diabetes; Type 2 Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2
Diabetes Mellitus, Type 2
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Recruiting
Completed
Unknown status
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Completed
Completed
Unknown status
Unknown status
Completed
Recruiting
Unknown status
Completed
Completed
Completed
Terminated
Terminated
Completed
Unknown status
Completed
Completed
Unknown status
Completed
Not yet recruiting
Completed
Completed
Completed
Terminated
Completed
Completed
Recruiting
Completed
Completed
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Enrolling by invitation
Terminated
Completed
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Withdrawn
Completed
Completed
Completed
Completed
Active, not recruiting
Recruiting
Completed
Completed
Completed
Completed
Completed
Recruiting
Terminated
Terminated
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Not yet recruiting
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Unknown status
Completed
Active, not recruiting
Completed
Recruiting
Completed
Not yet recruiting
Unknown status
Terminated
Completed
Completed
Terminated
Active, not recruiting
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Unknown status
Terminated
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Completed
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Terminated
Completed
Completed
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Withdrawn
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Recruiting
Completed
Not yet recruiting
Completed
Completed
Unknown status
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Not yet recruiting
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Completed
Active, not recruiting
Unknown status
Unknown status
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Unknown status
Unknown status
Active, not recruiting
Unknown status
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Unknown status
Completed
Completed
Recruiting
Completed
Unknown status
Completed
Unknown status
Unknown status
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Unknown status
Completed
Recruiting
Unknown status
Completed
Completed
Completed
Completed
Terminated
Terminated
Completed
Unknown status
Completed
Completed
Completed
Completed
Terminated
Active, not recruiting
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Saxagliptin Hydrate
OPC-262, BMS-477118, BMS-477118-11
Approved
Bristol-Myers Squibb Company
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT Number
NCT01768208
NCT02605772
NCT02471404
NCT02285985
NCT02917031
NCT02386943
NCT01527747
NCT02104739
NCT02965443
NCT03014479
NCT02304081
NCT02312427
NCT04521049
NCT01006590
NCT03700801
NCT02280486
NCT01548651
NCT02243176
NCT02765204
NCT01267448
NCT01765270
NCT02024477
NCT02307695
NCT02583438
NCT01608724
NCT02182895
NCT04445714
NCT02920801
NCT01206647
NCT01960205
NCT01552018
NCT02481479
NCT02089438
NCT01006603
NCT01660386
NCT02742233
NCT02407899
NCT02462369
NCT01107886
NCT02528019
NCT02365233
NCT01162876
NCT00885378
NCT00757588
NCT01634282
NCT00327015
NCT00666458
NCT02022007
NCT01319357
NCT01606007
NCT00295633
NCT01434186
NCT02551874
NCT02315495
NCT00575588
NCT01046318
NCT01242228
NCT00121641
NCT02419612
NCT00614939
NCT00661362
NCT00918138
NCT00698932
NCT00374907
NCT00121667
NCT03199053
NCT01646320
NCT01128153
NCT00960076
NCT01619059
NCT01204775
NCT01922817
NCT02946632
NCT02681094
NCT01193179
NCT02377388
NCT00683657
NCT00918879
NCT02104804
NCT02284893
NCT02273050
NCT00313313
NCT00316082
NCT00997282
NCT02547935
NCT03714594
NCT00857558
NCT00950599
NCT01521312
NCT02597101
NCT02223065
NCT01525225
NCT02060201
NCT00899470
NCT01068743
NCT01068717
NCT00897390
NCT01441869
NCT03169959
NCT01755494
NCT01582308
NCT03138356
NCT01192152
NCT01662999
NCT01305551
NCT01192139
NCT00935467
NCT01874080
NCT01365091
NCT00770302
NCT03933787
NCT02456428
NCT02969798
NCT02239458
NCT04017221
NCT02148978
NCT01086319
NCT01944618
NCT03918148
NCT02475499
NCT01552005
NCT01377935
NCT02476760
NCT02140645
NCT04170790
NCT02244164
NCT01575483
NCT01086306
NCT03492580
NCT01086280
NCT01767389
NCT01192659
NCT03939624
NCT01703637
NCT02613897
NCT03936023
NCT01223456
NCT02138097
NCT02588859
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus; Inadequate Glycaemic Control
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus; Heart Failure
Type 2 Diabetes
Type 2 Diabetes; Hypertriglyceridemia
Prediabetes; Obesity
Type 2 Diabetes
Type 2 Diabetes
Type2 Diabetes Mellitus
Heart Failure; Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Impaired Glucose Tolerance
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2; Severe Hyperglycemia - Blood Glucose Level >300mg/dl.
Type 2 Diabetes Mellitus; Cardiovascular Disease
Type 2 Diabetes
Type 1 Diabetes
Type 2 Diabetes; Obesity
Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Prediabetes
Coronary Artery Disease; Diabetes Mellitus Type 2
Diabetes Mellitus, Non-Insulin-Dependent; Heart Failure
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetic Foot Ulcer
Diabetes Mellitus, Type 1
Microalbuminuria; Microalbuminuria /Creatinine Ratios ACR
Type 2 Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type II Diabetes; Nonalcoholic Fatty Liver
Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes, Type 2
Diabetes
Type 2 Diabetes
Polycystic Ovary Syndrome; Disorder of Glucose Regulation
Diabetes Mellitus Type 2
Type 2 Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 1 Diabetes; Hypoglycaemia
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus; Inadequate Glycaemic Control
Diabetes, Type 2
Platelet Aggregation During Acute Myocardial Infarction
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes
Diabetes
Diabetes Type 2
Type 2 Diabetes Mellitus, CKD and Albuminuria
Type2 Diabetes Mellitus
Diabetes, Type 2
Type 2 Diabetes Mellitus
Impaired Glucose Tolerance
Type 2 Diabetes Mellitus; Insulin Resistance
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus(T2DM)
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Physical Activity; Sympathetic Nervous System; Secretion; Catecholamine
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2; Impaired Glucose Tolerance (IGT); Impaired Fasting Glucose (IFG)
Cystic Fibrosis
Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation
Cystic Fibrosis
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus (T2D)
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Erectile Dysfunction With Diabetes Mellitus; Drug Interaction
Type 2 Diabetes; Incretinomimetics; Pancreas
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type2 Diabetes; Myocardial Infarction; Ischemic Stroke; Cardiovascular Death; Heart Failure; All-Cause Mortality
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Unknown status
Unknown status
Completed
Completed
Completed
Unknown status
Enrolling by invitation
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Completed
Terminated
Completed
Completed
Unknown status
Terminated
Completed
Unknown status
Unknown status
Completed
Completed
Not yet recruiting
Completed
Unknown status
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Unknown status
Recruiting
Unknown status
Completed
Unknown status
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Unknown status
Completed
Unknown status
Completed
Terminated
Recruiting
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Active, not recruiting
Terminated
Completed
Completed
Sitagliptin/Ertugliflozin
Approved
Pfizer Pharmaceuticals Ltd (China)
Diabetes Mellitus, Type 2
Gemigliptin L-tartrate Sesquihydrate
LC-150444, LC-15-0444
Approved
Lg Life Sciences
Diabetes Mellitus, Type 2, Hepatic Insufficiency
NCT Number
NCT03202563
NCT02500329
NCT01890629
NCT01787396
NCT02343926
NCT01601990
NCT02126358
NCT02089126
NCT01602003
NCT02831361
NCT01968044
NCT01990469
NCT04255238
NCT03842267
NCT02250872
NCT01825850
NCT01662674
NCT01747083
NCT01595880
NCT01426399
NCT03355014
NCT02670018
NCT01823133
NCT01768455
NCT01426906
NCT04050098
NCT03565458
NCT03864432
NCT01001013
NCT04317703
NCT02670070
NCT02004587
NCT01603238
NCT02056600
NCT03310749
NCT02290301
NCT02186080
NCT02609815
Intervention Type
Procedure;Drug;Device
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Endothelial Function; Type 2 Diabetes; Gemigliptin; Acarbose
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes; Dyslipidemia
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 DM Patients With Moderate or Severe Renal Impairment
T2DM
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Cancer; Cisplatin Adverse Reaction
Healthy
Healthy
Type 2 Diabetes
Healthy
Healthy
Healthy Male Volunteers
Healthy
Healthy
Healthy
Healthy Male Volunteers
Type2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Healthy
Type 2 Diabetes
Healthy
Hepatic Impairment
Healthy
Healthy
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes
Study Phase
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
Recruitment Status
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Not yet recruiting
Not yet recruiting
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Not yet recruiting
Unknown status
Completed
Completed
Not yet recruiting
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Trelagliptin Succinate
SYR-111472 succinate, SYR-111472, TAK-472, SYR-472
Approved
Takeda Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT Number
NCT02528019
NCT02771093
NCT04374864
NCT03014479
NCT03231709
NCT01431807
NCT01751360
NCT02512068
NCT01632007
NCT03940183
NCT02324569
NCT00760344
NCT00653185
NCT02372097
NCT03555591
NCT04285983
NCT03362398
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type 2 Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Healthy
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 1
N/A
N/A
N/A
Recruitment Status
Unknown status
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Active, not recruiting
Recruiting
Completed
Sitagliptin Phosphate/Metformin Hydrochloride
Approved
Merck & Co Inc
Diabetes Mellitus, Type 2
NCT Number
NCT00993187
NCT01856907
NCT00532935
NCT01760447
NCT00541450
NCT00684528
NCT00838903
NCT00482729
NCT01076088
NCT01472367
NCT02882477
NCT04268563
NCT04192292
NCT01065766
NCT01357148
NCT03180281
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Disorder of Glucose Regulation
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus; Iron Metabolism Disorders; Gastroduodenal Ulcer; Optic Atrophy; Sensorineural Hearing Loss; Platelet Dysfunction
Polycystic Ovary Syndrome; Infertility; ART
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 1/Phase 2
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Recruiting
Active, not recruiting
Completed
Terminated
Unknown status
Linagliptin/Empagliflozin
BI 10773/BI 1356, BI 1356/BI 10773, BI 10773/linagliptin, Linagliptin/BI 10773, BI 1356/empagliflozin, Empagliflozin/BI 1356
Approved
C.H. Boehringer Sohn Ag & Co. Kg
Diabetes Mellitus, Type 2, Cardiovascular Diseases
NCT Number
NCT01422876
NCT02453555
NCT02489968
NCT02758171
NCT02815644
NCT03761797
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Healthy
Healthy
Diabetes Mellitus, Type 2
Study Phase
Phase 3
Phase 3
Phase 3
Phase 1
Phase 1
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Dapagliflozin/Saxagliptin/Metformin hydrochloride
Approved
Astrazeneca
Diabetes Mellitus, Type 2
Evogliptin
DA-1229
Approved
Dong-A Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2, Kidney Diseases, Aortic valve diseases, Liver Diseases
NCT Number
NCT04653779
NCT04521452
NCT02974504
NCT02587975
NCT03910361
NCT04584242
NCT02949193
NCT04170998
NCT02946541
NCT04356742
NCT03667300
NCT02689362
NCT04055883
NCT01941199
NCT02167061
NCT02954822
NCT02214693
NCT02754219
NCT02375139
NCT02267902
NCT00961025
NCT03766724
NCT04195919
NCT02753803
NCT04326166
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2; Renal Disease; Diabetes Mellitus; Metabolic Disease; Endocrine System Diseases
CAVD
Type2 Diabetes
Diabetes Mellitus, Type 2; Osteoporosis
Type2 Diabetes; Non-Alcoholic Fatty Liver Disease
Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
Type 2 Diabetes Mellitus
Type2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type2 Diabetes Mellitus; Albuminuria; Renal Insufficiency
Diabetes Mellitus, Type 2
Calcific Aortic Valve Disease
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type2 Diabetes
Renal Impairment
Liver Dysfunction
Type 2 Diabetes Mellitus
Healthy
Diabetes Mellitis Type 2
Type2 Diabetes
Hemodialysis Patients
Type 2 Diabetes
Diabetes Mellitus, Type 2
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Not yet recruiting
Not yet recruiting
Completed
Unknown status
Enrolling by invitation
Recruiting
Completed
Recruiting
Completed
Recruiting
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Unknown status
Completed
Not yet recruiting
Completed
Recruiting
Vildagliptin/Metformin Hydrochloride
LMF-237
Approved
Novartis Pharma Ag
Diabetes Mellitus, Type 2
NCT Number
NCT01604213
NCT01196546
NCT01518101
NCT02007278
NCT00468039
NCT00382096
NCT00396357
NCT01811485
NCT04081857
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus; Ischemic Heart Disease
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes; Hypoglycemia
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Health, Subjective
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Alogliptin Benzoate
SYR-322, TAK-322
Approved
Takeda
Diabetes Mellitus, Type 2, Acute Coronary Syndrome, Diabetes Mellitus
NCT Number
NCT02823808
NCT03014479
NCT04470310
NCT02763007
NCT01686711
NCT02771093
NCT03042325
NCT03231709
NCT02312427
NCT02528019
NCT02231021
NCT04392557
NCT02683226
NCT03794336
NCT01890122
NCT00856284
NCT00328627
NCT01456130
NCT02856113
NCT00286468
NCT00432276
NCT00306384
NCT01289119
NCT02276274
NCT01521962
NCT00655863
NCT00968708
NCT00286494
NCT02068443
NCT00395512
NCT00286429
NCT01023581
NCT00286442
NCT00707993
NCT00286455
NCT01318135
NCT01263509
NCT01318122
NCT01318070
NCT01318083
NCT01318109
NCT01263483
NCT01263470
NCT01263496
NCT00763347
NCT00755846
NCT01664624
NCT00957268
NCT01391663
NCT03501277
NCT02508168
NCT02798172
NCT02989649
NCT01945216
NCT01964963
NCT02221284
NCT03918148
NCT03555565
NCT03939624
NCT03492580
NCT01588587
NCT02756832
NCT01303055
NCT01964950
NCT04017221
NCT01964976
NCT01945242
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Heart Failure; Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Polycystic Ovary Syndrome; Insulin Resistance
Type 2 Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2
Clinical Pharmacology
Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics
Healthy Volunteers
Healthy Volunteers
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type2 Diabetes; Myocardial Infarction; Ischemic Stroke; Cardiovascular Death; Heart Failure; All-Cause Mortality
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Type 2 Diabetes Mellitus
Diabetes Mellitus
Diabetes Mellitus, Type 2
Surveillance
Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation
Surveillance
Type 2 Diabetes Melitus
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Recruiting
Completed
Active, not recruiting
Terminated
Completed
Completed
Withdrawn
Completed
Completed
Unknown status
Completed
Recruiting
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Completed
Completed
Completed
Completed
Anagliptin/Metformin Hydrochloride
SK-1501
Approved
Sanwa Kagaku Kenkyusho Co Ltd, Suzuken
Diabetes Mellitus, Type 2
Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline
MK-0431J
Approved
Merck & Co Inc, Astellas
Diabetes Mellitus, Type 2
NCT Number
NCT02577016
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 3
Recruitment Status
Completed
Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate
Approved
Mitsubishi Tanabe Pharma Corp, Daiichi Sankyo Co Ltd
Diabetes Mellitus, Type 2
Teneligliptin Hydrobromide Hydrate
MP-513
Approved
Mitsubishi Tanabe Pharma
Diabetes Mellitus, Type 2
NCT Number
NCT02449330
NCT02081599
NCT02512523
NCT02312427
NCT03014479
NCT03011177
NCT03508323
NCT04446026
NCT02528019
NCT02924064
NCT02314637
NCT00974090
NCT01301833
NCT01805830
NCT02354222
NCT02916706
NCT00998881
NCT01026194
NCT02354235
NCT01798238
NCT01072331
NCT02567994
NCT02220907
NCT00628212
NCT00971243
NCT03769870
NCT04431141
NCT03787017
NCT03009513
NCT03793023
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Heart Failure; Diabetes Mellitus
Type 2 Diabetes
Type2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Diabete Mellitus
Type 2 Diabetes Mellitus
Healthy Volunteers
Diabetes Mellitus
Type 2 Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Recruiting
Completed
Unknown status
Completed
Completed
Completed
Active, not recruiting
Recruiting
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Completed
Completed
Recruiting
Omarigliptin
MK-3102
Approved
Merck & Co Inc
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetes Mellitus
NCT Number
NCT02906709
NCT01697592
NCT01704261
NCT01703208
NCT01863667
NCT01717313
NCT01755156
NCT01841697
NCT01814748
NCT01682759
NCT01703221
NCT01698775
NCT01217073
NCT01767688
NCT01407276
NCT01088711
NCT03362398
NCT04365907
Intervention Type
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Chronic Renal Insufficiency; Type 2 Diabetes Mellitus
Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 2
Healthy Volunteers
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 1
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Terminated
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Sitagliptin Hydrochloride
Approved
Linagliptin
BI-1356, BI-1356-BS
Approved
Boehringer Ingelheim Gmbh
Diabetes Mellitus, Type 2, Albuminuria, Renal Insufficiency, Carcinoma, Transitional Cell, Hypertension, Hepatic Insufficiency
NCT Number
NCT01617824
NCT02240680
NCT02061969
NCT01512979
NCT01897532
NCT01438814
NCT02312427
NCT01547104
NCT02372630
NCT03014479
NCT02092597
NCT02280174
NCT02401880
NCT02041234
NCT02350478
NCT03642184
NCT02180334
NCT04341935
NCT03194945
NCT02004366
NCT02442817
NCT03320031
NCT03004612
NCT02106104
NCT01903070
NCT02097342
NCT01969084
NCT02528019
NCT03504566
NCT02072096
NCT02467478
NCT02453555
NCT00621140
NCT01888796
NCT01087502
NCT02752113
NCT04670666
NCT01422876
NCT01835678
NCT00800683
NCT01734785
NCT01968044
NCT03051243
NCT03429543
NCT01792518
NCT00996658
NCT01084005
NCT02851745
NCT00601250
NCT01214239
NCT01194830
NCT01215097
NCT04371978
NCT00954447
NCT02015299
NCT01708902
NCT02077309
NCT00602472
NCT00641043
NCT00819091
NCT01204294
NCT01183013
NCT02376075
NCT04134650
NCT00740051
NCT04542213
NCT00798161
NCT01243424
NCT00736099
NCT00915772
NCT01778049
NCT00622284
NCT02897349
NCT00654381
NCT00309608
NCT00716092
NCT03667300
NCT01012037
NCT04662866
NCT01342484
NCT00328172
NCT03869190
NCT03281369
NCT02084082
NCT02183532
NCT02183350
NCT02223026
NCT01947153
NCT01540487
NCT02821910
NCT03259490
NCT02183636
NCT02183376
NCT02212782
NCT02172222
NCT01943019
NCT02183441
NCT02183428
NCT02183389
NCT01276327
NCT02183415
NCT02084056
NCT02221401
NCT02758171
NCT02183298
NCT01845077
NCT02183480
NCT02220647
NCT01216397
NCT02183402
NCT02173639
NCT02183623
NCT02183584
NCT02183493
NCT00935220
NCT03629054
NCT02815644
NCT01703286
NCT02183506
NCT02183363
NCT02180503
NCT02183311
NCT02173665
NCT02183337
NCT02173652
NCT01581931
NCT01383356
NCT01189201
NCT02221414
NCT02857946
NCT03250052
NCT02191228
NCT02175394
NCT02121509
NCT02183467
NCT04017221
NCT02725502
NCT02138097
NCT02197078
NCT03918148
NCT01677104
NCT03807440
NCT03970668
NCT04180813
NCT01974544
NCT03222765
NCT03338803
NCT01707147
NCT01767389
NCT01904383
NCT01903356
NCT03939624
NCT01650259
NCT02792400
NCT02244164
NCT02140645
NCT03492580
NCT02608177
NCT01826370
NCT03470454
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Combination Product
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Combination Product
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure;Drug;Behavioral
Drug
Drug
Drug
Other
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes; Chronic Renal Failure
Diabetes Mellitus, Type 2
Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Heart Failure; Diabetes Mellitus
Diabetes Mellitus Type 2
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type II Diabetes in Subjects BMI 27 to 32
Type 2 Diabetes; Coronary Artery Disease
New Onset Diabetes After Transplant; Kidney Transplant; Complications
Diabetes Mellitus, Type 2
Coronavirus Infection; Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes
Schizophrenia
Type 2 Diabetes Mellitus; Peritoneal Dialysis
Prediabetic State; Insulin Resistance
Type 2 Diabetes
Diabetes Mellitus
Type 2 Diabetes Mellitus; Insulin Sensitivity/Resistance
Type II Diabetes Mellitus
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Diabetic Nephropathy Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes; Impaired Renal Function
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2 (T2DM); Left Ventricular Diastolic Dysfunction
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Type 2-diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 DM Patients With Moderate or Severe Renal Impairment
DM2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Left Ventricular Systolic Dysfunction
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
COVID 19; Coronavirus; Diabetes Mellitus, Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine System Diseases; Dipeptidyl-Peptidase IV Inhibitors; Linagliptin; Severe Acute Respiratory Syndrome Coronavirus 2; Sars-CoV2; Hypoglycemic Agents; Respiratory Tract Diseases; Incretins; Hormones
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus Type 2 (T2DM); Vascular Inflammation; Plaque Morphology
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Arterial Hypertension; Albuminuria
Prediabetic State; Insulin Resistance
Diabetes Mellitus, Type 2
Hyperglycemia; Covid19
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type2 Diabetes Mellitus; Albuminuria; Renal Insufficiency
Diabetes Mellitus, Type 2
Impaired Glucose Tolerance; Insulin Sensitivity; Glucose Metabolism Disorders
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Urothelial Carcinoma
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Healthy
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Hepatic Insufficiency
Healthy
Healthy
Schizophrenia
Healthy
Healthy
Healthy
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Diabetes Mellitus, Type 2
Healthy
Healthy
Healthy
Hypertension
Renal Insufficiency
Healthy
Healthy
Healthy
Diabetes Mellitus, Type 2; Urosepsis; Diabetic Ketoacidosis; Lower Extremity Amputation
Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes; Obesity
Diabetes Mellitus, Type 2
Transplanted Kidney Complication
Diabetes Mellitus, Type 2
Type 2 Diabetes
PreDiabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type2 Diabetes; Myocardial Infarction; Ischemic Stroke; Cardiovascular Death; Heart Failure; All-Cause Mortality
Diabetes Mellitus, Type 2
Type 2 Diabetes
Type 2 Diabetes; Incretinomimetics; Pancreas
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Chronic Kidney Diseases; Type 2 Diabetes
Diabetes Mellitus, Type 2
Kidney Function Affection Upon Exposure to Radiocontrast; Diabetes; Microalbuminuria
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Unknown status
Completed
Completed
Unknown status
Completed
Active, not recruiting
Completed
Recruiting
Completed
Not yet recruiting
Not yet recruiting
Completed
Completed
Unknown status
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Withdrawn
Terminated
Completed
Completed
Completed
Terminated
Completed
Completed
Not yet recruiting
Completed
Completed
Completed
Completed
Completed
Unknown status
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Completed
Completed
Recruiting
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Recruiting
Completed
Active, not recruiting
Completed
Recruiting
Unknown status
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Terminated
Completed
Alogliptin Benzoate/Pioglitazone Hydrochloride
SYR-322-4833 BL
Approved
Takeda Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT02683226
NCT02763007
NCT02823808
NCT03950505
NCT01990300
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Polycystic Ovary Syndrome; Insulin Resistance
Diabetes Mellitus, Type 2
Diabetes
Non-alcoholic Steatohepatitis; Type2 Diabetes
Type 2 Diabetes Mellitus
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
N/A
Recruitment Status
Completed
Terminated
Recruiting
Recruiting
Completed
Saxagliptin Hydrochloride/Metformin Hydrochloride
Approved
Astrazeneca
Diabetes Mellitus, Type 2
NCT Number
NCT01267448
NCT00885378
NCT02022007
NCT01305551
NCT01874080
NCT01754142
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Diabetes Mellitus Type 2; Severe Hyperglycemia - Blood Glucose Level >300mg/dl.
Type 2 Diabetes Mellitus
Polycystic Ovary Syndrome; Disorder of Glucose Regulation
Type 2 Diabetes
Diabetes
Diabetes Mellitus, Type 2
Study Phase
Phase 4
Phase 3
Phase 3
Phase 1
Phase 1
N/A
Recruitment Status
Unknown status
Completed
Completed
Withdrawn
Completed
Completed
Simvastatin/Sitagliptin Phosphate Monohydrate
MK-0431D
Withdrawn
Merck Sharp & Dohme Corp
Hypertriglyceridemia, Diabetes Mellitus, Type 2, Hyperlipoproteinemia Type II
NCT Number
NCT01678820
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 3
Recruitment Status
Terminated
HSK-7653
HSK7653, HSK-7653
Phase 3 Clinical
Liaoning Haisco Pharmaceutical Co Ltd, Sichuan Haisco Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT04564872
NCT04556851
NCT04540016
Intervention Type
Drug
Drug
Drug
Indications
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type II Diabetes
Study Phase
Phase 3
Phase 3
Phase 1
Recruitment Status
Recruiting
Recruiting
Recruiting
Diabetes therapeutic
DBPR-108
Phase 3 Clinical
Taiwan Shenlong Co Ltd, National Health Research Institutes
Diabetes Mellitus, Type 2
NCT Number
NCT04161430
NCT04124484
NCT01650324
NCT02163278
Intervention Type
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Study Phase
Phase 3
Phase 2
Phase 1
Phase 1
Recruitment Status
Not yet recruiting
Completed
Completed
Completed
Retagliptin Phosphate
SP-2086 Phosphate
Phase 3 Clinical
Jiangsu Hengrui Medicine Co Ltd
Diabetes Mellitus, Type 2, Renal Insufficiency
NCT Number
NCT04667143
NCT01970033
NCT01970046
NCT01984489
NCT01969357
NCT01969318
NCT02815748
NCT02817217
NCT02822534
NCT02500485
NCT02815787
NCT02815657
NCT02815774
NCT02815722
NCT02826044
NCT02813863
NCT02817243
NCT02821871
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug;Dietary Supplement
Indications
Diabetes Mellitus, Type II
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Renal Insufficiency
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
Study Phase
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Recruitment Status
Not yet recruiting
Unknown status
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Unknown status
Unknown status
Completed
Completed
Completed
Completed
Unknown status
Completed
Unknown status
Unknown status
Cetagliptin Phosphate
CGT-8012
Phase 3 Clinical
Shengshi Taike Biological Medicine Technology (Suzhou) Co Ltd
Diabetes Mellitus, Type 2, Carcinoma, Non-Small-Cell Lung
Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate
Phase 3 Clinical
Lg Life Sciences Ltd
Diabetes Mellitus, Type 2, Dyslipidemias
NCT Number
NCT02670070
NCT03867942
Intervention Type
Drug
Drug
Indications
Healthy
Diabetes Mellitus, Type 2; Dyslipidemias
Study Phase
Phase 1
Phase 1
Recruitment Status
Unknown status
Not yet recruiting
Fotagliptin Benzoate
Phase 3 Clinical
Chongqing Fuchuang Pharmaceuticals Research Co Ltd, Shanghai Fosun Industry Co Ltd
Diabetes Mellitus, Type 2
CPL2009-0031
Phase 3 Clinical
Cadila Healthcare Ltd
Diabetes Mellitus, Type 2
Dutogliptin Tartrate
REC-01, PHX-1149, PHX-1149T
Phase 2 Clinical
Phenomix
Diabetes Mellitus, Type 2, Myocardial Infarction, ST Elevation Myocardial Infarction, Kidney Diseases, Leukemia, Myeloid, Acute
NCT Number
NCT00998686
NCT00865592
NCT00690638
NCT00850239
NCT00947557
NCT00958269
NCT01089790
NCT00970424
NCT01101945
NCT00530881
NCT00482950
NCT03486080
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus; Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus; Renal Impairment
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Acute Myocardial Infarction; Acute Myocardial Ischemia; STEMI - ST Elevation Myocardial Infarction
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Recruitment Status
Terminated
Terminated
Completed
Terminated
Terminated
Terminated
Terminated
Terminated
Terminated
Completed
Unknown status
Enrolling by invitation
TQ-F3083
TQ-F3083
Phase 2 Clinical
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Sailintai Medicine Technology Co Ltd
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT Number
NCT03986073
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 2
Recruitment Status
Recruiting
Imigliptin Hydrochloride
KBP-3853
Phase 2 Clinical
Kbp Biosciences Co Ltd, Beijing Sihuan Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
Talabostat (BioXcel)
PT-100, BXCL-701
Phase 2 Clinical
Inveni
Pancreatic Neoplasms, Prostatic Neoplasms
NCT Number
NCT04123574
Intervention Type
Drug
Indications
Cancer of Pancreas; Cancer of the Pancreas; Neoplasms, Pancreatic; Pancreas Cancer; Pancreatic Cancer
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Yogliptin
Phase 2 Clinical
Sichuan Sunheal Pharmaceutical Co Ltd, Chengdu Easton Biopharmaceuticals Co Ltd
Diabetes Mellitus, Type 2
YS-110
YSCMA, YS-110
Phase 2 Clinical
Y'S Therapeutics
Carcinoma, Renal Cell, Mesothelioma
NCT Number
NCT03177668
Intervention Type
Drug
Indications
Malignant Pleural Mesothelioma
Study Phase
Phase 1/Phase 2
Recruitment Status
Completed
Linagliptin/Fimasartan Potassium Trihydrate
Phase 1 Clinical
Boryung Pharmaceutical Co Ltd
Hypertension, Diabetes Mellitus
NCT Number
NCT03609294
Intervention Type
Drug
Indications
Hypertension; Diabetes
Study Phase
Phase 1
Recruitment Status
Completed
HD118
HD-118
Phase 1 Clinical
Huadong Medicine, Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
TSL-0319
TSL-0319
Phase 1 Clinical
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
Evogliptin Tartrate
LY-05007
Phase 1 Clinical
Dong-A Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT02167061
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 1
Recruitment Status
Completed
DC291407
DC-407, DC-291407
Phase 1 Clinical
Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Diabetes Mellitus, Type 2
Lobeglitazone/Sitagliptin
CKD-396
Phase 1 Clinical
Chong Kun Dang
Diabetes Mellitus, Type 2
NCT Number
NCT04246190
Intervention Type
Drug
Indications
Type2 Diabetes Mellitus
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Sitagliptin/Telmisartan
HOB-077, HDDO-1609, HDDO-16091 + HDDO-16092
Phase 1 Clinical
Hyundai Pharmaceutical
Hypertension, Diabetes Mellitus
Augliptin Hydrochloride
Phase 1 Clinical
Shanghai Yangfan Pharmaceutical Technology Co Ltd, Nanjing Chang'Ao Medicine Technology Co Ltd
Diabetes Mellitus, Type 2
Bogliptin maleate
HL012MA
Phase 1 Clinical
Shanghai Runshi Pharmaceutical Technology Co Ltd
Solid tumours
REC-04
Clinical
Recardio
Cardiovascular Diseases
Gemigliptin L-tartrate Sesquihydrate/Glimepiride
Pending
Lg Life Sciences
Diabetes Mellitus, Type 2
PBL-1427
PBL-1427
Pending
Panacea
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT Number
NCT01554293
Intervention Type
Drug
Indications
Diabetes Mellitus
Study Phase
Phase 1
Recruitment Status
Unknown status
Melogliptin
GRC-8200, EMD-675992
Pending
Glenmark Pharmaceuticals
Diabetes Mellitus, Type 2
NCT Number
NCT00836940
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 2
Recruitment Status
Unknown status
KR-66195
KR-66195, KR-66222
Pending
Korea Research Institute Of Chemical Technology
Diabetes Mellitus, Type 2
Besigliptin Tosilate
SHR-117887
Pending
Hansoh Pharma
Diabetes Mellitus, Type 2
NCT Number
NCT01984489
Intervention Type
Drug
Indications
Type 2 Diabetes
Study Phase
Phase 2
Recruitment Status
Completed
GW-825964
825964, GW-825964
Pending
Glaxosmithkline Plc
Diabetes Mellitus, Type 2
ARI-2243
ARI-2243
Pending
Arisaph
Diabetes Mellitus, Type 2
ZYDPLA-1
ZYDPLA-1
Pending
Zydus Cadila
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT Number
NCT02620592
Intervention Type
Drug
Indications
Diabetes Mellitus
Study Phase
Phase 1
Recruitment Status
Completed
Retagliptin Phosphate/Metformin Hydrochloride
Pending
Jiangsu Hengrui Medicine Co Ltd
Diabetes Mellitus, Type 2
IP-10.C9
IP-10.C9
Pending
Imtm
Inflammatory Bowel Diseases
IP10C8
IP10-C8, IP10.C8
Pending
Imtm
Acne Vulgaris, Psoriasis
NCT Number
NCT00824980
Intervention Type
Drug
Indications
Psoriasis
Study Phase
Phase 2
Recruitment Status
Unknown status
NGP-20368
NGP-20368
Discontinued
Wuhan Maide Pharmaceutical Technology
Diabetes Mellitus, Type 2
R-1438
R-1438
Discontinued
F. Hoffmann-La Roche Ltd
Diabetes Mellitus, Type 2
RO-0730699
RO-0730699, DPP-IV inhibitor-Roche, CD26 antigen antagonist-Roche
Discontinued
F. Hoffmann-La Roche Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT00111670
Intervention Type
Drug
Indications
Diabetes Mellitus Type 2
Study Phase
Phase 2
Recruitment Status
Completed
NVP-728
DPP-728, NVP-728, NVP-DPP-728
Discontinued
Novartis Pharma Ag
Diabetes Mellitus, Type 2
ABT-279
ABT-279, A-804693
Discontinued
Abbvie Inc
Diabetes Mellitus, Type 2
PSN-9301
P-9301, P-93/01, PSN-9301
Discontinued
Astellas Pharma Inc
Diabetes Mellitus, Type 2
TS-021
TS-021
Discontinued
Taisho Pharmaceutical
Diabetes Mellitus, Type 2
Begelomab
BT 5/9, SAND-26
Discontinued
Adienne
Graft vs Host Disease
NCT Number
NCT02411084
Intervention Type
Biological
Indications
Graft vs Host Disease
Study Phase
Phase 3
Recruitment Status
Terminated
Pioglitazone Hydrochloride/Sitagliptin Phosphate Monohydrate
K-0431C
Discontinued
Merck & Co Inc
Diabetes Mellitus, Type 2
NCT Number
NCT02502721
Intervention Type
Drug
Indications
Healthy
Study Phase
Phase 1
Recruitment Status
Completed
TAK-100
TAK-100
Discontinued
Takeda Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2
ER-260891
E-3024, ER-260891
Discontinued
Eisai Co Ltd
Diabetes Mellitus
ALS-2-0426
AMG-222, ALS-2-0426
Discontinued
Amgen Inc
Diabetes Mellitus, Type 2
Carmegliptin
R-1579, RG-1579, DPP-IV(3), RO-4876904, RO-4876904-001
Discontinued
F. Hoffmann-La Roche Ltd
Diabetes Mellitus, Type 2
NCT Number
NCT00502710
Intervention Type
Drug
Indications
Diabetes Mellitus Type 2
Study Phase
Phase 2
Recruitment Status
Completed
SSR-162369
SSR-162369
Discontinued
Sanofi
Diabetes Mellitus, Type 2
P-3298
P-3298, P-32/98
Discontinued
Vivoryon Therapeutics
Diabetes Mellitus, Type 2
BI-14332
BI-14332, BI-14332CL
Discontinued
Boehringer Ingelheim Gmbh
Diabetes Mellitus, Type 2
BMS-767778
BMS-767778
Discontinued
Bristol-Myers Squibb Company
Diabetes Mellitus, Type 2
NCT Number
NCT00707590
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 1
Recruitment Status
Terminated
Atorvastatin Calcium Hydrate/Sitagliptin Phosphate Monohydrate
MK-0431E
Discontinued
Merck & Co Inc
Atherosclerosis, Diabetes Mellitus
Denagliptin tosilate
GW-823093, GW-823093C
Discontinued
Glaxosmithkline Plc
Diabetes Mellitus, Type 2
NCT Number
NCT00387972
NCT00370942
NCT00111800
NCT00372957
Intervention Type
Drug
Drug
Drug
Drug
Indications
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Study Phase
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Recruitment Status
Withdrawn
Terminated
Completed
Completed
TA-6666
T-6666, TA-6666
Discontinued
Mitsubishi Tanabe Pharma Corp
Diabetes Mellitus, Type 2
PT-630
PT-630, Glu-boroPro
Discontinued
Midatech Pharma Us Inc
Diabetes Mellitus, Type 2
KRP-104
KRP-104
Discontinued
Kyorin
Diabetes Mellitus, Type 2
NCT Number
NCT00995345
NCT00525330
Intervention Type
Drug
Drug
Indications
Type 2 Diabetes
Type 2 Diabetes
Study Phase
Phase 2
Phase 2
Recruitment Status
Completed
Completed
Linagliptin/Pioglitazone Hydrochloride
Discontinued
C.H. Boehringer Sohn Ag & Co. Kg
Diabetes Mellitus, Type 2
NCT Number
NCT02183636
Intervention Type
Drug
Indications
Healthy
Study Phase
Phase 1
Recruitment Status
Completed
Dutogliptin Tartrate/Metformin Hydrochloride
Discontinued
Phenomix Corporation
Diabetes Mellitus, Type 2
NCT Number
NCT00482950
Intervention Type
Drug
Indications
Type 2 Diabetes Mellitus
Study Phase
Phase 2
Recruitment Status
Unknown status